Trial Profile
Investigator-initiated Expanded access program for cannabidivarin in drug resistant epilepsy and autism
Status:
Recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 04 Feb 2019
Price :
$35
*
At a glance
- Drugs Cannabidivarin (Primary)
- Indications Autistic disorder; Epilepsy
- Focus Adverse reactions; Expanded access; Therapeutic Use
- 04 Dec 2019 Planned number of patients changed from 10 to 20 according to results presented at the 72nd Annual Meeting of the American Epilepsy Society
- 04 Dec 2018 Results (n=5) presented at the 72nd Annual Meeting of the American Epilepsy Society
- 27 Nov 2018 According to a GW Pharmaceuticals media release, initial data (n=5) will be presented at the American Epilepsy Society.